IGBA calls for full transparency and new timelines for impact assessment with regard to the voluntary WHO biological qualifier (BQ) proposal

The International Generic and Biosimilar medicines Association (IGBA) welcomes the WHO’s continuous interest in the development of a global identification system for biological substances, as well as the decision to perform an impact study assessment of the voluntary Biological Qualifier (BQ) proposal. However, IGBA does not support the BQ proposal since successful product identification and tracking using multiple identification components are already in force, such as the brand name or the INN combined with the company name, the lot number and various national codes.


Statement by the International Generic and Biosimilar Medicines Association on the Signing of the Trans-Pacific Partnership Agreement

February 4, 2016 – Geneva, Switzerland – The International Generic and Biosimilar Medicines Association (IGBA) represents companies that are actively engaged in the global manufacturing and trading systems for medicines. We support enhanced cooperation between regulators to foster the global trade in medicines, as well as measures aimed at the elimination of barriers to trade in medicines in order to increase access for patients.

Contact Info


Rue de Cornavin 11
1201 Geneva, Switzerland

Telephone: +32 (0)477438729 (S. Kox)
This email address is being protected from spambots. You need JavaScript enabled to view it.  
Secretary General –   This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site